While the addition of anthracyclines to taxane-based chemotherapy regimens does improve clinical outcomes in patients with early-stage HER2-negative breast cancer, the benefit needs to be balanced with the risk of toxicity [20]. The gene discussed is ERBB2; the disease is breast carcinoma.